Profile data is unavailable for this security.
About the company
Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.
- Revenue in USD (TTM)50.83m
- Net income in USD-171.53m
- Incorporated2022
- Employees113.00
- LocationScilex Holding Co960 San Antonio RoadPALO ALTO 94303United StatesUSA
- Phone+1 (650) 516-4310
- Fax+1 (302) 636-5454
- Websitehttps://www.scilexholding.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elutia Inc | 24.99m | -70.10m | 136.24m | 54.00 | -- | -- | -- | 5.45 | -3.05 | -2.86 | 1.12 | -2.28 | 0.5303 | 2.32 | 5.08 | 462,722.20 | -148.77 | -42.93 | -1,212.93 | -79.34 | 42.46 | 43.32 | -280.53 | -64.16 | 0.6842 | -0.6561 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 138.32m | 217.00 | -- | 1.02 | -- | 43.51 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| Eton Pharmaceuticals Inc | 31.38m | -6.69m | 140.03m | 30.00 | -- | 10.37 | -- | 4.46 | -0.2596 | -0.2596 | 1.22 | 0.5229 | 1.00 | 8.82 | 7.89 | 1,046,033.00 | -21.31 | -46.22 | -38.27 | -58.20 | 59.48 | 72.16 | -21.31 | -76.86 | 1.28 | -- | 0.2571 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| Hongchang International Co Ltd | 4.65m | -292.22k | 140.08m | 8.00 | -- | 3.57 | -- | 30.13 | -0.0006 | -0.0006 | 0.0093 | 0.0757 | 0.1647 | 5.02 | 8.74 | -- | -0.8827 | -7.98 | -0.9331 | -10.94 | 3.92 | 11.47 | -5.36 | -64.88 | 3.77 | -- | 0.2642 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| Lifecore Biomedical Inc | 128.26m | 9.33m | 154.49m | 524.00 | 33.74 | 13.51 | 8.49 | 1.20 | 0.1482 | 0.2318 | 3.83 | 1.76 | 0.5055 | 2.14 | 4.26 | 244,774.80 | 3.68 | -5.91 | 4.35 | -8.33 | 32.63 | 31.01 | 7.27 | -19.16 | 1.06 | 0.2373 | 0.6923 | -- | 24.20 | -25.46 | 114.53 | 34.47 | -16.72 | -- |
| Biostem Technologies Inc | 131.44m | 7.87m | 166.13m | 67.00 | 30.48 | 9.17 | 20.55 | 1.26 | 0.3346 | 0.3346 | 7.31 | 1.11 | 2.80 | 7.41 | 3.35 | -- | 16.78 | -- | 107.11 | -- | 94.73 | -- | 5.98 | -- | 1.20 | 15.52 | 0.2012 | -- | -- | -- | -- | -- | -- | -- |
| Procaps Group SA | 414.10m | 52.20m | 189.54m | 5.50k | 3.23 | 4.81 | 2.72 | 0.4577 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| Mediwound Ltd | 20.14m | -19.97m | 189.63m | 100.00 | -- | 9.14 | -- | 9.41 | -2.16 | -2.16 | 2.18 | 1.92 | 0.3311 | 5.53 | 6.55 | 201,410.00 | -32.83 | -24.48 | -49.28 | -32.92 | 13.25 | 43.27 | -99.17 | -38.43 | 1.51 | -3.26 | 0.2623 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| ASP Isotopes Inc | 2.30m | -27.05m | 190.72m | 76.00 | -- | 13.54 | -- | 83.08 | -0.628 | -0.628 | 0.0549 | 0.2112 | 0.068 | -- | -- | 30,206.32 | -71.81 | -- | -89.44 | -- | 36.54 | -- | -1,055.85 | -- | -- | -8.11 | 0.6748 | -- | -- | -- | -229.34 | -- | -- | -- |
| Scilex Holding Co | 50.83m | -171.53m | 191.79m | 113.00 | -- | -- | -- | 3.77 | -1.40 | -1.40 | 0.4425 | -1.77 | 0.4401 | 5.22 | 1.55 | 484,123.80 | -102.93 | -- | -- | -- | 68.24 | -- | -233.88 | -- | 0.1853 | -3.72 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| Greenwich Lifesciences Inc | 0.00 | -10.22m | 195.59m | 3.00 | -- | 33.09 | -- | -- | -0.7942 | -0.7942 | 0.00 | 0.4496 | 0.00 | -- | -- | 0.00 | -112.41 | -36.43 | -123.67 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
| Amylyx Pharmaceuticals Inc | 298.76m | -165.87m | 211.06m | 384.00 | -- | 0.8077 | -- | 0.7064 | -2.45 | -2.45 | 4.34 | 3.84 | 0.7605 | 3.69 | 15.91 | 778,026.10 | -42.22 | -- | -50.91 | -- | 84.64 | -- | -55.52 | -- | 4.66 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -18.74m | 232.14m | 1.00 | -- | 148.09 | -- | -- | -0.6855 | -0.6855 | 0.00 | 0.0529 | 0.00 | -- | -- | 0.00 | -467.16 | -- | -686.91 | -- | -- | -- | -- | -- | -- | -0.9299 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Inhibrx Biosciences Inc | 1.85m | 1.63bn | 235.67m | 166.00 | 0.1343 | 1.07 | 0.144 | 127.18 | 121.21 | 121.21 | 0.0434 | 15.15 | 0.0079 | -- | 4.86 | 11,162.65 | 693.63 | -77.06 | 815.31 | -93.91 | -- | -- | 88,264.55 | -1,590.91 | -- | -21.96 | 0.00 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Rigel Pharmaceuticals Inc | 130.30m | -14.23m | 242.11m | 147.00 | -- | -- | -- | 1.86 | -0.8136 | -0.8136 | 7.45 | -1.70 | 1.06 | 1.05 | 5.24 | 886,401.40 | -11.59 | -28.82 | -19.93 | -47.26 | 92.41 | 97.88 | -10.92 | -35.76 | 1.48 | -1.73 | 2.00 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
Data as of Sep 23 2024. Currency figures normalised to Scilex Holding Co's reporting currency: US Dollar USD
12.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 7.42m | 4.09% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 5.55m | 3.06% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.95m | 2.18% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.29m | 0.71% |
| Millennium Management LLCas of 31 Mar 2024 | 1.07m | 0.59% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 885.30k | 0.49% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 676.02k | 0.37% |
| D. E. Shaw & Co. LPas of 31 Mar 2024 | 627.04k | 0.35% |
| Rafferty Asset Management LLCas of 31 Mar 2024 | 620.13k | 0.34% |
| BlackRock Advisors LLCas of 31 Mar 2024 | 580.20k | 0.32% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
